Introduction
In normal individuals, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the first and second most common nonmelanoma skin cancers (NMSC), respectively. [1] [2] [3] Squamous cell carcinoma is the most common skin cancer in patients who are receiving immunosuppressive therapy following solid organ transplantation. 4 The relationship between immunological function and skin cancer was first reported in 1971 when Walder et al. reported that 7 (14%) of 51 kidney allograft recipients developed a total of 16 SCCs over a period of 4-45 months after transplantation. Although the association between immunodeficiency and development of lymphoreticular tumors was well-established, Walder's report suggested that immunosuppressive treatment may also precipitate the development of SCC. 5 Subsequent studies confirmed the association between solid organ transplantation/immunosuppression and the development of SCC, BCC and other skin neoplasms. [6] [7] [8] The relative risk for such tumors in solid organ recipients is estimated to be 92 and 108 for women and men, respectively. 9 Bone marrow transplantation is associated with an increased incidence of secondary malignancies; conventional, myeloablated transplant recipients are at increased risk for malignant melanoma and SCC of the buccal cavity and skin. 10, 11 Chronic graft-versus-host disease (cGVHD) appears to be an important risk factor for the development of secondary skin cancer. [12] [13] [14] [15] The relative contributions of severity, duration and treatment of GVHD with regard to risk for skin cancer has yet to be determined.
Recent innovative immunosuppressive conditioning regimens permit allogeneic engraftment without ablating the marrow. [16] [17] [18] [19] [20] [21] These transplants are characterized by high engraftment rates, low transplant-related mortality and evidence for disease responses and survival. A truly nonmyeloablative regimen does not eradicate host hematopoiesis and should allow relatively prompt autologous hematopoietic recovery without a transplant. 22 Nonmyeloablative allogeneic transplantation (NMAT) is being increasingly used to treat a variety of malignant and nonmalignant disorders, and is now considered a viable therapeutic option for the treatment of advanced hematological malignancies. [17] [18] [19] [20] To date, no cases of secondary skin cancer have been reported in recipients of allogeneic hematopoietic cells following nonmyeloablative conditioning. The following report describes several patients who developed skin cancer after undergoing NMAT.
Methods

Nonmyeloablative protocol
In an effort to better define the role of NMAT, a research protocol was developed in May of 2000 for the treatment of advanced hematological malignancies by the Stem Cell Transplant Program and the IU Cancer Center. The protocol took into consideration the specific type of malignancy, stage of disease and subject age. For inclusion in the study, all subjects were required to have an HLA-matched (MRD) or partially matched sibling (6/6 or 5/6) or a 6/6 matched unrelated donor (MUD) capable of undergoing granulocyte colony-stimulating factor mobilization and apheresis. In general, patients had (1) advanced hematological malignancies, high-risk myelodysplasia (MDS) or high-risk acute myelogenous leukemia (AML) in remission at the time of transplant; (2) relapse postautograft or (3) chemorefractory disease. The Institutional Review Board at Indiana University approved the study and all patients gave informed consent.
Conditioning, graft-versus-host disease prevention and transplant methodology Patients (both related and unrelated recipients) were conditioned with cyclophosphamide, 120 mg/kg, and fludarabine, 125 mg/m 2 . GVHD prophylaxis consisted of cyclosporine (CSA) 3 mg/kg/day, initiated on day -1 and continued until the patient tolerated oral administration, with target whole-blood trough levels of 200-300 mg/dl by fluorescent polarization immunoassay (Abbott, Chicago, IL, USA). In an effort to optimize GVHD prophylaxis, subjects 31 through 49 also received mycophenolate mofetil (MMF) at a dose of 1000 mg b.i.d. intravenous/posttransplant beginning on day þ 1 after transplant. The primary objective was achievement of donor cell engraftment. Secondary objectives included the following: (1) identification of transplant-related toxicity; (2) determination of the incidence and severity of GVHD; (3) measurement of time to resolution of cytopenias. The National Cancer Institute Common Toxicity Criteria version 2.0 was used for the evaluation of regimen-related toxicity. 23 Graft-versus-host disease was graded by an established GVHD severity scale. 24, 25 The median age for all subjects was 55 years (range, 17-66 years). All related (n ¼ 26, 53.1%) or unrelated (n ¼ 23, 46.9%) donors were fully matched at HLA-A, HLA-B and HLA-DR loci (molecular or serological class I typing and molocular typing of Class II). 26 All patients were followed until death or at least 7 months (range, 25-1675 days; median, 413 days).
Results
Details of results including engraftment, chimerism, disease response, regimen-related toxicity, graft-versus-host reactions and disease-free and overall survival have been submitted for publication. 27 Briefly, all patients engrafted. The rate of grade 3 or 4 aGVHD was 28.6% and extensive cGVHD, 57.2%. Eighteen skin cancer lesions, including SCC (n ¼ 14), BCC (n ¼ 2) and malignant melanoma (n ¼ 2), were diagnosed in six patients; all were excised without dissemination. Baseline characteristics of patients with skin cancer are shown in Table 1 and compared with those without skin cancer in Table 2 .
Case descriptions of patients with skin cancer Patient 1. A 61-year-old female with MDS developed grade 4 (gastrointestinal, no skin) aGVHD 92 days post transplant. She developed BCC day þ 805. At day þ 1604, she is alive, in complete remission, and receiving no immunosuppressive therapy.
Patient 2.
A 62-year-old male with secondary acute myelogenous leukemia (t-AML) and a prior history of SCC experienced no aGVHD following MRD transplant, but developed cGVHD limited to the skin day þ 121 post transplant. He was diagnosed with SCC at day þ 120 that was excised. He died of progressive AML on day þ 191. resected without complication or dissemination; he has experienced no recurrences over the last 24 months and is currently receiving no immunosuppressive therapy.
Discussion
Multiple skin cancers were identified in six patients (five patients in the MRD group and one in the MUD group). These occurred exclusively in the patients with t-AML or MDS and were diagnosed from 2 to 26 months (mean, 12 months) following transplantation. All skin cancers were completely excised and none were disseminated at diagnosis or became disseminated. The median age of those with skin cancer was 60.5 years versus 55 years in the 43 patients who did not develop skin cancer (P ¼ 0.164). All patients with skin cancer had prior cGVHD, which was extensive in all but one and all except one (the only MUD) had skin involvement as part of their cGVHD diagnosis. The incidence of cGVHD in those without skin cancer was not statistically different compared to those who developed skin cancer (P ¼ 0.167). There was also no difference in time to onset of cGVHD in those with or without skin cancer (P ¼ 0.188). Table 3 summarizes the patients' cGVHD and skin cancer characteristics. Previous studies demonstrate an association between solid organ transplantation and an increased risk for solid cancers, particularly SCCs. [7] [8] [9] 28, 29 Conventional BMT also appears to increase the risk of developing skin cancer, particularly squamous cell of the skin and buccal cavity. [10] [11] [12] [13] [14] Curtis et al.
14 compared clinical characteristics of 183 patients who developed secondary cancers (58 SCCs, 125 non-SCCs) and 501 matched control patients within a Table 3 Chronic GVHD in six patients who developed skin cancer after NMAT 11 reported a cohort of 56 patients that were followed for a minimum of 40 months following conventional BMT for aplastic anemia and leukemias; three patients developed secondary malignancy of the skin or oral mucosa, including two SCCs and one melanoma. Hasegawa et al. found that 16 of 557 recipients followed from 8 to 32 years after BMT developed skin cancer (BCC, n ¼ 5 and SCC, n ¼ 11). Overall, BCC and SCC comprised 45.7% of the secondary malignancies reported and 14 of the 16 (87.5%) recipients had prior cGVHD. Time to development of secondary skin cancers ranged from 4.4-8.8 years. 10 The current study shows for the first time that patients who undergo NMAT are at risk for developing skin cancer. Although the sample size is small, the extreme incidence points toward an association and suggests that myeloablative conditioning is not a requirement for the development of skin neoplasms. We found six patients who developed skin cancer over a median time of 14 months with a maximum time of follow-up of 4.5 years. The incidence of developing skin cancer after NMAT was significantly higher compared to the cohort reported by Hasegawa et al. (P ¼ o0.0009, Fisher's exact test) and not significant compared to Lishner et al. (P ¼ 0.171). Of note, all of the patients who underwent NMAT who later developed skin cancer had an initial diagnosis of MDS or AML compared to those transplanted for other conditions (P ¼ 0.031).
Given the NMAT strategy of administering intensive immunosuppression to establish donor hematopoiesis, the risk for development of skin cancer is not surprising; the association between immunosuppression and malignant neoplasms of the skin, particularly SCC, following solid organ transplantation is well-documented. [30] [31] [32] Adequate numbers of activated CD4 þ T-lymphocytes have been postulated to inhibit malignant transformation of precursor skin lesions. 33, 34 Features of these observations of particular interest include the following: (1) there was a striking incidence of secondary skin cancers; (2) the secondary skin cancers appeared relatively early after intense, short-term immunosuppression, which contrasts with that observed after solid organ transplantation; and (3) there was a predilection for patients with prior t-AML/MDS. This latter association is especially noteworthy, and suggests that patients with t-AML/MDS harbor a constitutional tendency towards the development of skin cancer. Alternatively, patients with AML/MDS, who generally receive intensive chemotherpy prior to transplantation, are subject to intensification or prolongation of the immunosuppressive effects related to conditioning compared to other types of hematological malignancies. In this regard, however, three of the six with skin cancer in the present series did not receive intensive induction therapy. Another possible confounding factor is the prior history of skin cancer, as was present in Patient 2. It is impossible to determine that the skin cancer does not merely represent a recurrence of prior skin cancer, particularly given the short interval between the onset of cGVHD and SCC; however, he had no overt evidence of SCC when they presented for transplantation. Additionally, there were no patients (including patient 2) with histological demonstrations of scar within any of the resected lesions. As for patient 6, who developed multiple skin cancers beginning at day þ 79, prior to the development of cGVHD, it is plausible that prior treatment for Crohn's disease may have resulted in intensified immunosuppression, putting him at especially increased risk for developing secondary skin cancer. The association between Crohn's disease treated with azathioprine and other immunosuppressive agents and skin cancer is well described. 35, 36 Among purine analogues, fludarabine may in itself increase the risk for development of secondary skin cancers. Fludarabine phosphate is metabolized to the active antimetabolite, 2-fluoro-ara-ATP, which incorporates into DNA, resulting in DNA inactivation and apoptosis. Fludarabine also inhibits DNA-polymerase, RNA-polymerase, DNA-ligase, DNA-primase and ribonucleotidereductase. 37, 38 It is conceivable that the addition of fludarabine to a cyclophosphamide-containing regimen prevents repair of double-stranded breaks introduced by the alkylating agent. Fludarabine depletes CD3 þ , CD4 þ , and CD8 þ lymphocytes over a period of many months. 39, 40 Larsen et al. 41 reported metastatic SCC in one patient following treatment with fludarabine and in another after 2-CdA. Davidovitz et al. 42 reported a patient with a flare of scalp SCC following treatment with fludarabine. Rashid et al. 43 reported four patients who developed aggressive skin cancers (3 BCC and 1 SCC) following treatment with fludarabine.
Another putative mechanism for the development of skin cancer is human papillomavirus-associated carcinogenesis. 44 HPV-associated cancers express oncoproteins that inactivate certain tumor suppressor genes, including p53. [45] [46] [47] Kutler et al. 48 utilized PCR techniques to detect HPV DNA in SCCs obtained from 24 patients with Fanconi anemia (FA); HPV DNA was detected in 84% of the SCCs obtained from patients with FA and in 36% of SCCs from control patients. Mutations of p53 are strongly associated with the development of BCC and SCC with approximately 56% of BCC and 490% of SCCs harbor p53 mutations. 49, 50 Analysis of our cohort's skin cancers for HPV DNA and evidence for p53 mutation is currently underway.
Conclusion
The association between both solid organ and conventional marrow transplantation and the development of skin cancer is well established. The finding of skin cancers in six of 43 patients treated with NMAT suggests that even nonmyeloablative transplantation techniques and relatively short-term immunosuppression does not elimiSkin cancer after nonmyeloablative transplantation M Cavalier et al nate skin cancer risk in the post transplantation setting and further underscores the need for vigilant skin cancer surveillance.
